Hyderabad: Hetero-based Player Player Hetero has received authorization of emergency use (EUA) from the drug controller General India (DCGI) for limited use of the generic version of Todilizumab in India.
Hetero Menilizumab Biosimilar, which has been named Tocira, has been given a nod for covid-19 patients who have been hospitalized and receive systemic corticosteroids and require additional oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Hetero’s Tocira 400mg / 20ml, which is a biosimriar version of Actemra and Roercra Roche, will be launched from September End, said Hetero Group on Monday.
This drug will be produced by Hetero’s Biologics Arm Hetero Biopharma in a special biologics facility based in Jadcherla in Hyderabad.
Tocira will be marketed by Hetero’s Associate Company Hetero Healthcare in India.
Commenting on Development, Hetero Group B Partha Saradhi Reddy said EUA’s nod to Tocira showed technical capabilities and hetero commitments to bring important therapies relevant to Covid care.
“This agreement is very important for supply security in India by considering the deficiency of Global Tocilizumab.
We will work with the government to ensure fair distribution,” Reddy said.
Hetero’s Tililizumab Biosimilar received NOD DCGI for Covid-19 patients treated at the hospital
